Professional Documents
Culture Documents
829_BIOZENTA_LIFESCIENCE_PVT._LTD._company_brochure_20220917234302
829_BIOZENTA_LIFESCIENCE_PVT._LTD._company_brochure_20220917234302
com
I
ABOUT US
BIOZENTA Lifesciences was established in 2018 with a deep emphasis to serve humanity
through Quality and affordable critical medicines, with an aim of HUMAN HELPING HUMAN
connecting with human life for “DELIEVERING HOPE TO HUMAN SPIRIT”.
BRIEF HISTORY OF COMPANY FOUNDER:
Company Founder Mr. Deep Narayan Sharma is a graduate in Pharmacy & MBA in production
management having a vast experience in Pharmaceuticals manufacturing. After working at top
management levels in various pharmaceutical companies, he started his venture in the Year 2011
under the name of M/s Dr. Aarbidee Laboratories and Aarya Healthcare (A Division for Food
Products) which has been later on taken over by M/s Biozenta Lifescience Pvt. Ltd. and he became
the Founder & Managing Director of the company. Under his leadership, "Biozenta" achieved new
milestones and offered many innovative medicines for the Critical care specialty in Oncology
products. Mr. Deep believes in hard work with honesty and tries to achieve companies' self-made
financial goals by working smartly and ethically. This envision the company's motto of "Human
Helping Human".
VISION STATEMENT:
To become a leading and most valued global company, that can provide affordable quality
medicine to cure the most ailing.
To care for those who are in real need to survive.
MISSION STATEMENT:
To produce and market safe, effective, quality, and affordable medicines and healthcare products
that will heal and alleviate human life.
To earn a reputation of quality manufacturer & marketer, to serve global medical fraternity &
humanity with affordable and quality medicines for treating critical diseases.
FORMULATION AND DEVELOPMENT:
We at BIOZENTA, strive to identify and develop new, meaningful product formulations related to
Critical Care and Oncology segments. We are actively expanding global F&D capabilities and
advancing our clinical pipeline in therapeutic areas that leverage our expertise.
Our Formulation development program currently includes clinical development programs in the
areas of Critical care and oncology for new product candidates, line extensions for existing
products, and the generation of additional clinical data for existing products.
QUALITY STATEMENT:
Quality is an integral part of the organization. Production is conducted in compliance with
applicable quality regulations, codes, and standards ... Records, documentation, and data are
provided in accordance with applicable regulations. Our products are duly checked and approved
by terminal quality auditors. Thus, we offer such products that are safe, compliant, and preferred.
We are committed towards cGMP concept with respect to “ZERO tolerance on stability and quality
of the products”.
QUALITY POLICY:
At BIOZENTA, we are committed to manufacturing products of highest quality standards, with an
endeavour to achieve total customer satisfaction and Continual improvement towards quality
delivering as per customer requirements.
Amphotericin-B, Liposomal Injection as Lyophilized. Amphotericin-B, Emulsion Injection 5mg/ml. Paclitaxel (Protein Bound Particle) for Injectable
Suspension as Lyophilized.
Eribulin Mesylate Solution for Injection Triptorelin for Injection as Lyophilized, Triptorelin for Injection as Lyophilized,
Strength-0.88 mg/2ml. Strength- 3.75 mg. Strength-11.25 mg/vial.
Daunorubicin Citrate Liposome Injection, Car lzomib for Injection Strength- 60mg/vial. Fulvestrant Injection Strength-250mg/5ml.
Strength-50 mg/25 ml.
Decitabine for Injection(As Lyophilized) Daunorubicin Liposome, 50 mg per 25 ml. Doxorubicin Hydrochloride Liposome Injection
Strength- 50mg/vial. (As Pegylated Liposome).
www.biozenta.com
I
BIOZENTA LIFESCIENCE PVT. LTD.
KHASRA NO. 59, 60 & 61, BELA BATHRI, HAROLI, UNA, HIMACHAL PRADESH, 174301 INDIA
PRODUCT LIST (CYTOTOXIC)
Sr. No. Generic Name
1 Capecitabine Tablets USP 150/500 mg
2 Gefitinib Tablets 250 mg
3 Erlotinib Tablets 100/150 mg
4 Anastrozole Tablets 1.0 mg
5 Imatinib Tablets 100/400 mg
6 Methotrexate Tablets 2.5/5.0/7.5/15 mg
7 Everolimus Tablets 5.0/10 mg
8 Abiraterone Acetate Tablets USP 250/500 mg
9 Lapatinib Tablets 250 mg
10 Sorafenib Tablets 200/250 mg
11 Letrozole Tablets USP 2.5 mg
12 Tamoxifen Tablets BP 10/20/40 mg
13 Mercaptopurine Tablets 50 mg
14 Dasatinib Tablets 50/70/100 mg
15 Nilutamide Tablets 150 mg
16 Letrozole Tablet USP 2.5 mg
17 Flutamide Tablet 250 mg
18 Exemestane Tablet 25 mg
19 Fludarabine Phosphate Tablet 10 mg
20 Melphalan Tablets BP 2.0/4.0 mg
21 Mitotane Tablet USP 500 mg
22 Megestrol Acetate Tablet USP 40 mg/160 mg
23 Axitinib Tablet 1.0 mg, 5.0 mg
24 Pazopanib Tablet 200 mg, 400 mg
25 Valganciclovir Tablets USP 450
26 Deferasirox Tablets 125 mg , 250 mg, 500 mg
27 Regorafenib Tablets 40 mg
28 Osimertinib Tablets 40 mg, 80 mg
29 Mycophenolate Mofetil Tablets 360/750/500 mg
30 Afatinib tablets 20/30/40/50 mg
31 Sirolimus Tablets 1mg/2mg
32 Mesna Tablets 400mg/600mg
33 Entecavir Tablets 0.5mg/ 1mg
34 Tofacitinib Tablets 5mg
35 Etoposide Capsules 50/100 mg
36 Vinorelbine Injection 10 mg/ml/50mg/5ml
37 Ibandronic Acid Injection 1.0 mg/ml /6mg/6ml
38 Leucovorin Calcium Injection 50 mg / 5 ml
39 Epirubicin Injection BP 10 mg/5 ml/50mg/25ml
40 Doxorubicin Injection 10 mg/5ml/50mg/25ml
41 Mesna Injection 100 mg/ml
42 Thalidomide Capsules USP 50/100/200 mg
43 Temozolomide Capsules 5.0/20/100/250 mg
44 Imatinib Capsules 100/400mg
45 Lenalidomide Capsules 5.0/10/15/25 mg
46 Sunitinib Maleate Capsules 12.5/25/50 mg
API Manufacturing
Our technology upgraded and regulatory compliance Oncology API business is boosted by our R&D centre at
Industrial Area, Tahliwal, Dist.-Una, Himachal Pradesh, where a team of dedicated scientists is working to develop a
cost-effective and non infringing chemical processes following regulatory guidelines. the R&D centre is fully equipped with
current safety equipment, including an isolator lab and a separate facility for hydrogenation reactions,as well as unique
provisions forlow and high temperature reactions (-80 to +250 oC) and cyanation expertise.
Mfg. Site (Oncology): Khasra No. 59, 60 & 61, Bela Bathri, Una, (HP) – 174301, India.
API Manufacturing Unit (Oncology): Ind. Area, Tahliwal, Una, (HP) 174303, India.
Corporate Office: E-177, Industrial Area, Phase-7, Mohali. 160055 (Punjab), India.
Regd. Office: DNA House, B3, Opp. Godrej Interio, Raipur, Roorkee, (UK) 247661, India.
Biogracea Medicare: Ind. Area, Tahliwal, Dist-Una (HP) 174303, India.
+91 78070 96338 +91 78070 96337 +91 98161 02847 | bd@biozenta.com | export@biozenta.com | biozenta@gmail.com
www.biozenta.com